{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-018212","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.598081+00:00","generated_at":"2026-05-26T01:28:51.935394+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Iovance Q4 2024 product revenue $73.7M; FY24 total $164.1M, achieving upper end of guidance","bullets":["Full year 2024 product revenue of $164.1M, within $160-165M guidance; Amtagvi $103.6M, Proleukin $60.5M.","Net loss FY24 $372.2M ($1.28/share) vs $444.0M ($1.89/share) in FY23.","Reaffirms FY25 product revenue guidance of $450-475M; FY25 cash burn expected under $300M.","Cash position ~$422M as of Feb 26, 2025, expected to fund operations into H2 2026.","Dan Kirby named Chief Commercial Officer in Feb 2025; Raj Puri promoted to Chief Regulatory Officer Nov 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-018212","json":"https://secwatch.observer/filing/0001104659-25-018212.json","markdown":"https://secwatch.observer/filing/0001104659-25-018212.md","text":"https://secwatch.observer/filing/0001104659-25-018212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/0001104659-25-018212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/tm257755d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:28:51.935394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}